Brown et al., 2015 [19] |
Australia |
Cohort study |
50-preterm |
50
months |
Extremely preterm |
IQ <70, congenital anomalies, CP,
a visual or hearing impairment |
MABC-2 |
≤15th percentile |
15
(30) |
Dewey et al., 2019 [20] |
Australia |
Cohort study |
162-preterm |
7
years |
Very preterm |
CP |
MABC-2 |
<16th percentile |
53
(32.7) |
Doyley et al., 2014 [21] |
Multicenter (Canada, Australia, Europe,
Israel) |
Randomized clinical trial |
698-preterm (placebo group) |
5
years |
Classification by birth weight |
IQ ≤69, CP, blindness |
MABC |
≤5th percentile |
106 (16.5) |
Garbi et al., 2022 [22] |
France |
Cross-Sectional |
114-preterm |
7
to 10 years |
Extremely preterm |
Autism, mental delay, CP |
Touwen
Infant Neurological Examination |
Unclear |
12 (11) |
Hua et al., 2021 [9]
|
China
|
Cohort study
|
20676-preterm
115376-full-term
|
3 to 5 years
|
Very preterm, moderate/late preterm
|
Visual,
hearing, or intellectual impairments or
other severe developmental disorders
|
LDCDQ
|
≤15th percentile
|
4326 (20.9)
|
Kwok et al., 2019 [23] |
Canada |
Cohort study |
165-preterm |
4.5
years |
Very preterm |
CP, global developmental delay, intellectual
impairment, visual or hearing impairments |
MABC-2 |
≤5th percentile |
29 (17.6) |
Lahti et al., 2020 [24] |
Finland |
Cohort study |
37-preterm |
11
years |
Very preterm |
Congenital anomalies or syndromes, CP,
neuromuscular disorders |
MABC-2 |
≤5th percentile |
8
(22.2) |
Losch, Dammann, 2004 [25] |
Germany |
Cohort study |
298-preterm |
6 years |
Classification by birth
weight |
CP, ADHD |
Touwen Infant Neurological Examination |
Unclear |
56 (18.8) |
Örtqvist, Einspieler, Ådén, 2021 [26] |
Sweden |
Cohort study |
32-preterm |
12 years |
Extremely preterm |
Malformations, chromosome
aberrations,
malignant disorders, CP, blindness, autism
|
MABC - 2 |
≤5th
percentile |
15 (44) |
Setänen et al., 2016 [27] |
Finland |
Cohort study |
90-preterm |
11
years |
Very preterm |
Intellectual disability, neurological disorder,
CP |
MABC-2 and DCDQ 07 |
≤5th percentile |
8 (8.8) |
Sustersic, Sustar, Paro-Panjan, 2012 [28] |
Slovenia |
Cohort study |
41-preterm |
5 to 6 years |
Preterm |
CP |
MABC |
≤15th percentile |
7
(17) |
Uusitalo et al., 2020 [29] |
Finland |
Cohort study |
170-preterm |
11 years |
Very preterm |
Congenital anomalies, syndrome affecting
cognitive development, CP |
MABC-2 |
≤5th percentile |
18
(11.2) |
Wocadlo, Rieger, 2008 [30] |
Australia |
Cohort study |
323-preterm |
8 yeays |
Very preterm |
CP,
blindness, hearing impairment, IQ<76, |
BOTMP |
<
15th percentile |
101 (31.3) |
Zamir et al., 2021 [31] |
Sweden |
Cohort study |
345-preterm |
6.5
years |
Extremely preterm |
Cerebral palsy |
MABC-2 |
≤5th percentile |
76 (22.2) |
Zwicker et al., 2013 [32] |
Canada |
Cohort study |
157-preterm |
4
to 5 years |
Extremely preterm |
CP, IQ<70, blind |
MABC |
≤15th percentile |
65 (42) |